Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
SRK Fund I, LP returned a stellar 46.94% during the first half of 2025, vastly outperforming the S&P 500 (6.20%) and Russell 2000 (-1.78%). ISSC and SLSN...
— Sean Kirkwood
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on ImmuCell Corporation
ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves.
ImmuCell Corporation ($ICCC) is an animal health company focused on developing and commercializing preventative biological products, led by its flagship First Defense franchise that treats calf scours (severe neonatal diarrhea in dairy and beef calves). The manager's bullish...